Skip to content
Open access

CD24 Acts as an Evolutionarily Conserved Innate Immune Checkpoint in Colorectal Cancer

Aug 2026 · bioRxiv · 0 citations · 25 references
Biology

TL;DR

CD24 is identified as an innate immune checkpoint that protects colorectal tumors from macrophage-mediated clearance through an evolutionarily conserved recognition mechanism, and its loss enables them to adopt a highly motile, tumor-directed, and functionally engaged state, characterized by increased fusion activity and myeloid intercellular interactions.

Abstract

Checkpoint immunotherapy has transformed cancer treatment, yet current approaches targeting adaptive immunity benefit only a subset of patients, leaving innate immunity as a largely untapped therapeutic frontier. Here, we identify CD24 as an innate immune checkpoint that protects colorectal tumors from macrophage-mediated clearance through an evolutionarily conserved recognition mechanism. Using zebrafish xenografts of isogenic colorectal cancer (CRC) cell lines, SW480 and SW620, we show that high CD24 expression in SW620 correlates with an immune-evasive, macrophage-resistant phenotype. Loss of human CD24 dramatically sensitizes tumors to clearance in zebrafish, while pharmacological macrophage depletion abolishes this effect. Mechanistically, CD24 suppresses innate immunity in a multilayered fashion, by limiting myeloid recruitment, dampening TNFα-driven macrophage inflammatory polarization, and blocking phagocytosis. Live imaging further revealed that CD24 constrains macrophages to a restrained, patrol-like state, and that its loss enables them to adopt a highly motile, tumor-directed, and functionally engaged state, characterized by increased fusion activity and myeloid intercellular interactions. We show that zebrafish macrophages respond to human CD24 despite extensive evolutionary divergence, and glycocalyx profiling revealed broad remodeling of the tumor cell surface upon CD24 loss, suggesting evolutionary conservation of sialic acid-dependent receptor recognition. Transcriptomic analyses identified the Siglec-like gene si:dkey-24p1.7 as a candidate zebrafish macrophage-expressed receptor mediating this response. Finally, analysis of TCGA CRC cohorts revealed that CD24 expression is a stage-dependent prognostic marker, underscoring the clinical relevance of this axis. Together, these findings establish CD24 as a critical orchestrator of innate immune evasion in CRC, while further validating zebrafish xenografts as a powerful platform for dissecting innate immuno-oncobiology in vivo. Graphical abstract

Read PDF

Similar papers

Review Open access Oct 2026

Innate immune cells in tumor immunity: dual roles, mechanistic insights, and therapeutic opportunities

The tumor microenvironment (TME) is a complex ecosystem that dynamically regulates tumor progression and therapeutic responses. Within this environment, innate immune cells play prominent dual roles, acting as both critical mediators of anti-tumor surveillance and facilitators of tumor immune escape. This review compre...

Song-Hang Xing, Jia-Yu Zhang, Shuang Wang et al. · 0 citations
Review Open access Sep 2026

Targeting innate immunity in cancer: mechanistic foundations, therapeutic vaccination, and clinical translation

This Review discusses the heterogeneity, dysfunction and therapeutic targeting of dendritic cells, macrophages, natural killer cells, neutrophils, myeloid-derived suppressor cells, innate lymphoid cells and other tissue-resident populations and considers how innate adjuvants, antigen selection, delivery technologies an...

Xing-Han Li, Yi-Tong Meng, Ji-Jun Dong et al. · 0 citations
Review Open access Sep 2026

Myeloid-derived suppressor cells in cancer: biology, regulatory networks and theranostic prospects

This review systematically summarizes the classification and identification of myeloid-derived suppressor cells, their biological properties in the context of tumors and autoimmune diseases, genetic and signaling pathway regulatory mechanisms, differentiation skewing in the TME, and cellular interactions with the TME.

Rong-Jun Deng, Xiu-Yun Bai, Jue Yang et al. · 0 citations
Open access Oct 2026

ACKR3 Establishes a Squamous-Restricted Immune Checkpoint Axis in Lung Squamous Cell Carcinoma.

Lung squamous cell carcinoma (LUSC) is an aggressive subtype of non-small cell lung cancer with limited targeted therapeutic options and incompletely defined immune-regulatory dependencies. Here, we identified atypical chemokine receptor 3 (ACKR3) as a squamous-enriched regulator that restrains malignant progression in...

Angeliki Karatza, Kaan Kumru, Jaylen M. Powell et al. · 0 citations
Review Open access Oct 2026

Targeting inhibitory phagocytosis checkpoints in cancer immunotherapy: mechanisms, therapeutic strategies, and translational challenges

Tumors evade macrophage-mediated clearance through mechanistically distinct but functionally convergent anti-phagocytic pathways. This review examines canonical and emerging receptor–ligand “don’t eat me” axes, Siglec-dependent glyco-inhibitory checkpoints, and an emerging noncanonical glycocalyx barrier associated wit...

Jie Li, Mei Ding, Jian Sun et al. · 0 citations
Oct 2026

Epigenetic Priming Sensitizes Metastatic Breast Cancer to Checkpoint Blockade by Rewiring the Tumor-Immune Microenvironment.

Work using metastatic mouse models shows that the antitumor response is multifactorial, comprising downregulation of myeloid-mediated CD8+ T-cell suppression along with increased B-cell and plasma cell activation, antibody production, and tertiary lymphoid structure (TLS) maturation.

Yaiza Senent, R. Manguso · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.